ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market. (Source: Reuters: Health)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Powered by Versicherungsvergleich